Apoptotic cell clearance in systemic lupus erythematosus: II. Role of β2-glycoprotein I
暂无分享,去创建一个
A. Tincani | A. Manfredi | S. Heltai | M. Sabbadini | P. Rovere | G. Nebbia | G. Balestrieri | G. Galati
[1] J. Davoust,et al. Apoptotic cell clearance in systemic lupus erythematosus. I. Opsonization by antiphospholipid antibodies. , 1998, Arthritis and rheumatism.
[2] M. Khamashta,et al. Endothelial cells as target for antiphospholipid antibodies. Human polyclonal and monoclonal anti-beta 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent beta 2-glycoprotein I and induce endothelial activation. , 1997, Arthritis and rheumatism.
[3] Francesca Granucci,et al. Maturation Stages of Mouse Dendritic Cells in Growth Factor–dependent Long-Term Cultures , 1997, The Journal of experimental medicine.
[4] L. Espinoza,et al. Induction of Experimental Antiphospholipid Antibody Syndrome in PL/J Mice Following Immunization With β2GPI , 1997, American journal of reproductive immunology.
[5] A. Tincani,et al. The anti-beta2-glycoprotein I activity in human anti-phospholipid syndrome sera is due to monoreactive low-affinity autoantibodies directed to epitopes located on native beta2-glycoprotein I and preserved during species' evolution. , 1996, Journal of immunology.
[6] G. Willems,et al. Role of divalency in the high-affinity binding of anticardiolipin antibody-beta 2-glycoprotein I complexes to lipid membranes. , 1996, Biochemistry.
[7] S Gordon,et al. Role for the class A macrophage scavenger receptor in the phagocytosis of apoptotic thymocytes in vitro. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[8] A Sali,et al. Site-directed mutagenesis of recombinant human beta 2-glycoprotein I identifies a cluster of lysine residues that are critical for phospholipid binding and anti-cardiolipin antibody activity. , 1996, Journal of immunology.
[9] C. Haslett,et al. Human monocyte-derived macrophage phagocytosis of senescent eosinophils undergoing apoptosis. Mediation by alpha v beta 3/CD36/thrombospondin recognition mechanism and lack of phlogistic response. , 1996, The American journal of pathology.
[10] A. Tsutsumi,et al. Antibodies to β2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus , 1996 .
[11] M. Walsh,et al. Anti-phospholipid autoantibodies bind to apoptotic, but not viable, thymocytes in a beta 2-glycoprotein I-dependent manner. , 1996, Journal of immunology.
[12] R. Roubey. Immunology of the antiphospholipid antibody syndrome. , 1996, Arthritis and rheumatism.
[13] E. Clementi,et al. CD95 engagement releases calcium from intracellular stores of long term activated, apoptosis-prone gammadelta T cells. , 1996, Journal of immunology.
[14] M. Petri,et al. Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[15] J. Lasala,et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. , 1995, The Journal of clinical investigation.
[16] C. Reutelingsperger,et al. Ultrastructural Detection of Surface Exposed Phosphatidylserine on Activated Blood Platelets , 1995, Thrombosis and Haemostasis.
[17] M. Khamashta,et al. Epitope specificity of monoclonal anti-beta 2-glycoprotein I antibodies derived from patients with the antiphospholipid syndrome. , 1995, Journal of immunology.
[18] S. Adelstein,et al. Immunization of a rabbit with beta 2-glycoprotein I induces charge-dependent crossreactive antibodies that bind anionic phospholipids and have similar reactivity as autoimmune anti-phospholipid antibodies. , 1995, Journal of immunology.
[19] Y. Shoenfeld,et al. Early onset of autoimmunity in MRL/++ mice following immunization with β2 glycoprotein I , 1995, Clinical and experimental immunology.
[20] L. Sammaritano,et al. Specificities and characteristics of beta 2 glycoprotein I-induced antiphospholipid antibodies. , 1995, The Journal of laboratory and clinical medicine.
[21] M. Ferrarini,et al. Daudi lymphoma killing triggers the programmed death of cytotoxic V gamma 9/V delta 2 T lymphocytes. , 1995, Journal of immunology.
[22] A. Tincani,et al. Anti-beta 2-glycoprotein I antibodies: a marker of antiphospholipid syndrome? , 1995, Lupus.
[23] H. Steller. Mechanisms and genes of cellular suicide , 1995, Science.
[24] D. Harrison,et al. Cell death in health and disease: the biology and regulation of apoptosis. , 1995, Seminars in cancer biology.
[25] R. Eisenberg,et al. "Anticardiolipin" autoantibodies recognize beta 2-glycoprotein I in the absence of phospholipid. Importance of Ag density and bivalent binding. , 1995, Journal of immunology.
[26] R. Roubey. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other "antiphospholipid" autoantibodies. , 1994, Blood.
[27] A. Tincani,et al. Beta 2 glycoprotein I and placental anticoagulant protein I in placentae from patients with antiphospholipid syndrome. , 1994, The Journal of rheumatology.
[28] S. Santoro. Antiphospholipid antibodies and thrombotic predisposition: underlying pathogenetic mechanisms [editorial; comment] , 1994 .
[29] T. Yasuda,et al. Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface , 1994, The Journal of experimental medicine.
[30] J. Hunt,et al. The fifth domain of beta 2-glycoprotein I contains a phospholipid binding site (Cys281-Cys288) and a region recognized by anticardiolipin antibodies. , 1994, Journal of immunology.
[31] D. Isenberg,et al. Immunoelectrophoresis and ELISA techniques for assay of plasma beta 2 glycoprotein-1 and the influence of plasma lipids. , 1993, Thrombosis research.
[32] S. Pierangeli,et al. Induction of phospholipid‐binding antibodies in mice and rabbits by immunization with human β2 glycoprotein 1 or anticardiolipin antibodies alone , 1993, Clinical and experimental immunology.
[33] S. Krilis,et al. Identification of a region of beta 2-glycoprotein I critical for lipid binding and anti-cardiolipin antibody cofactor activity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[34] C. Haslett,et al. Different populations of macrophages use either the vitronectin receptor or the phosphatidylserine receptor to recognize and remove apoptotic cells. , 1992, Journal of immunology.
[35] J. Buyon,et al. Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon beta 2-glycoprotein I. , 1992, The Journal of clinical investigation.
[36] T. Sumida,et al. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. , 1992, Journal of immunology.
[37] R. Derksen,et al. Lupus Anticoagulant Activity Is Frequently Dependent on the Presence of β2-Glycoprotein I , 1992, Thrombosis and Haemostasis.
[38] M. Raff,et al. Social controls on cell survival and cell death , 1992, Nature.
[39] V. Fadok,et al. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. , 1992, Journal of immunology.
[40] Hunt,et al. A Phospholipid-β2-Glycoprotein I Complex Is an Antigen for Anticardiolipin Antibodies Occurring in Autoimmune Disease But Not with Infection , 1992, Lupus.
[41] M. Lockshin,et al. Antiphospholipid antibody syndrome: immunologic and clinical aspects. , 1990, Seminars in arthritis and rheumatism.
[42] E. Harris,et al. Special report. The Second International Anti-cardiolipin Standardization Workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) group. , 1990, American journal of clinical pathology.
[43] T. Barbui,et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor , 1990, The Lancet.
[44] C. Chesterman,et al. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[45] S. Santoro,et al. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. , 1990, Annals of internal medicine.
[46] P. Henson,et al. Tissue injury in inflammation. Oxidants, proteinases, and cationic proteins. , 1987, The Journal of clinical investigation.
[47] A. Wyllie,et al. Apoptosis: A Basic Biological Phenomenon with Wide-ranging Implications in Tissue Kinetics , 1972, British Journal of Cancer.
[48] T. Tomiyama,et al. A NEW AMINO-COMPOUND IN THE JACK BEAN AND A CORRESPONDING NEW FERMENT.(I) , 1929 .
[49] S. Shapiro,et al. The lupus anticoagulant/antiphospholipid syndrome. , 1996, Annual review of medicine.
[50] M. Bottone,et al. Etoposide at different concentrations may open different apoptotic pathways in thymocytes. , 1996, European journal of histochemistry : EJH.
[51] M. Bottone,et al. A single-step staining procedure for the detection and sorting of unfixed apoptotic thymocytes. , 1993, European journal of histochemistry : EJH.
[52] C. Haslett,et al. Phagocyte recognition of cells undergoing apoptosis. , 1993, Immunology today.
[53] C. Chesterman,et al. Immunology and clinical importance of antiphospholipid antibodies. , 1991, Advances in immunology.
[54] D. Mosher. Physiology of thrombospondin. , 1990, Annual review of medicine.
[55] G. Kostner,et al. Investigations on beta 2-glycoprotein-I in the rat: isolation from serum and demonstration in lipoprotein density fractions. , 1980, The International journal of biochemistry.